A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

Inclusion Criteria:

- Advanced or metastatic cancer.

- Able to swallow tablets.

- For Part B, you will need to have colon cancer or non-small cell lung (NSCLC) cancer
with KRAS and/or BRAF mutations.

- Discontinued all previous treatments for cancer and recovered from the acute effects
from the therapy.

Exclusion Criteria:

- Active infection (fungal, viral, or bacterial).

- Active cancer in your brain or spinal cord.

- Acute or chronic leukemia.

- Serious heart condition.

- Disease that requires immunosuppressant therapy.

- Diagnosis of inflammatory bowel disease.

- Major small bowel resection that interferes with your body's ability to absorb the
oral medicine.

- Participated in other clinical trials investigating prexasertib or ralimetinib.

- Pregnant or breastfeeding.

- Other pre-existing conditions or medical history which your doctor will explain to
you.